Related Experiment Videos
Malignant osteopetrosis manifested as juvenile chronic myeloid leukemia
Pediatric Hematology and Oncology
|April 1, 1993
Summary
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Significant clinical and radiologic response to targeted therapy in pediatric cervicomedullary low-grade gliomas harboring the BRAFV600E mutation.
Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery·2025
Optimization of ciliary body cyclophotocoagulation settings: a randomized and controlled pilot study.
Canadian journal of ophthalmology. Journal canadien d'ophtalmologie·2025
In vitro and in vivo efficacy of non-psychoactive cannabidiol in neuroblastoma.
Current oncology (Toronto, Ont.)·2016
Hematopoietic stem cell donation: psychological perspectives of pediatric sibling donors and their parents.
Bone marrow transplantation·2015
The burden of childhood cancer in Nigeria - a focus on leukemia and lymphoma: epidemiology, biology, and health system challenges.
Pediatric hematology and oncology·2026
Current Perspective: The Role of Liquid Biopsy in Diagnosis and Management of Pediatric Rhabdomyosarcomas (RMS).
Pediatric hematology and oncology·2026
Neuromuscular Changes During the Six-Minute Walk Test in Pediatric Sickle Cell Disease.
Pediatric hematology and oncology·2026
Early discharge for low-risk pediatric febrile neutropenia: safe only in selected centers.
Pediatric hematology and oncology·2026
Clinical and microbiological characteristics of viridans group streptococcal bacteremia in pediatric and adolescent patients with cancer.
Pediatric hematology and oncology·2026
Development of cecal volvulus after redo pancreas transplantation.
Journal of surgical case reports·2026
Primary Diffuse Large B-Cell Lymphoma of the External Auditory Canal with Extensive Local Extension: A Case Report and Literature Review.
Iranian journal of otorhinolaryngology·2026
Comparison of variably specific Bruton tyrosine kinase inhibitors on platelet aggregation mediated by Fcγ receptor (FcγR) IIa, glycoprotein VI, and platelet endothelial aggregation receptor (PEAR) 1: implications for Bruton tyrosine kinase inhibitors as antithrombotic therapy.
Research and practice in thrombosis and haemostasis·2026